Abstract:e21151 Background: Immunotherapy (IO) is the standard of care in 1L stage IV non-small cell lung cancer (NSCLC) cases that are not eligible for targeted therapies. Today, a level of PD-L1 expression of 50% or above is the only standard predictive biomarker for IO efficacy as monotherapy. However, a majority of patients fail to respond to the treatment and are exposed to potentially severe immune-related adverse events. There is thus an urgent need to discover new predictive signatures of response to IO in such setting. Methods: A retrospective 1-year cohort of 63 patients with advanced NSCLC, PD-L1 expression > 50%, and treated with 1L pembrolizumab monotherapy was analyzed to develop a machine learning-based algorithm predictive of response to immunotherapy. Multimodal baseline data were collected including clinical, biological, pathology, molecular, baseline CT scan data and clinical outcomes status (objective response at first evaluation, PFS, OS). For each patient, thoracic tumors were segmented in 3D by both an experimented pneumologist and a radiologist using the SOPHiA DDM for Radiomics platform. Radiomics features were then extracted following the IBSI standards and combined with the other data modalities. A filter-based variable selection method was applied before testing several machine learning algorithms to obtain an individual prediction of the response at first evaluation. The optimization criterion was the Area Under the ROC Curve (AUC). Due to the small size of the cohort, a nested leave-pair-out cross-validation was used to properly estimate the model performance. Results: A logistic regression algorithm reached an AUC of 0.85, a precision of 83%, a sensitivity of 77% and a specificity of 74% for predicting response at first evaluation. The algorithm was able to correctly predict 21 progressions among 28 observed and 27 disease controls among 35 observed. Features with highest weight were representative of the full scope of data modalities included in the model, highlighting the importance of a truly multimodal analysis. Indeed, withdrawing any specific data modality (e.g., radiomics features), led to a decrease of at least ̃10% of the AUC. Patients were then stratified into two groups, progression versus disease control, based upon their predicted response status at first evaluation. These two groups displayed a statistically significant difference in PFS (p < 0.001), suggesting that baseline multimodal data analysis could help predict long-term outcomes. Conclusions: This proof-of-concept study suggests that machine learning applied to baseline multi-modal data can help predict response to IO at the individual patient level, as well as stratify patients to inform long-term outcomes. This algorithm is being improved and validated through a large real-world multicentric international observational study including more than 4000 patients (DEEP-Lung-IV study, NCT04994795).

Machine learning predicts treatment sensitivity in multiple myeloma based on molecular and clinical information coupled with drug response

Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data

Machine Learning Models for Predicting Multiple Myeloma Staging and MGUS Progression Using Gene Expression Data

Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment

Combining clinical and molecular data for personalized treatment in acute myeloid leukemia: A machine learning approach

A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer.

Informing immunotherapy with multi-omics driven machine learning

Radiomic-Based Prediction of Lesion-Specific Systemic Treatment Response in Metastatic Disease

Advancing drug-response prediction using multi-modal and -omics machine learning integration (MOMLIN): a case study on breast cancer clinical data

18F‑FDG PET/CT Based Radiomics Features Improve Prediction of Prognosis: Multiple Machine Learning Algorithms and Multimodality Applications for Multiple Myeloma

Abstract 5141: Using single cell gene expression to develop treatment response predictions in multiple myeloma

Machine learning applications in breast cancer survival and therapeutic outcome prediction based on multi-omic analysis

Machine learning-informed liquid-liquid phase separation for personalized breast cancer treatment assessment

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data

Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data

Machine Learning Approach for Rapid, Accurate Point-of-Care Prediction of M-Spike Values in Multiple Myeloma

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

Multimodal machine learning model prediction of “individual” response to immunotherapy in 1L stage IV NSCLC.